ES2038669T3 - Formulacion farmaceutica. - Google Patents

Formulacion farmaceutica.

Info

Publication number
ES2038669T3
ES2038669T3 ES87307973T ES87307973T ES2038669T3 ES 2038669 T3 ES2038669 T3 ES 2038669T3 ES 87307973 T ES87307973 T ES 87307973T ES 87307973 T ES87307973 T ES 87307973T ES 2038669 T3 ES2038669 T3 ES 2038669T3
Authority
ES
Grant status
Grant
Patent type
Prior art keywords
units
density
pharmaceutical formulation
dosage
tienenuna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87307973T
Other languages
English (en)
Inventor
John Michael Newton
Jane Elizabeth Devereux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London School of Pharmacy Innovations Ltd
Original Assignee
London School of Pharmacy Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds

Abstract

EL TIEMPO DE RESIDENCIA EN EL ESTOMAGO HUMANO DE UNIDADES SOLIDAS FARMACEUTICAS DE LIBERACION GASTRICA CONTROLADA, AUMENTA SIGNIFICATIVAMENTE SI LAS UNIDADES TIENEN UNA DENSIDAD QUE ES MUCHO MAS ALTA QUE LA NORMAL. UNA FORMA DE ADMINISTRACION ORAL PREFERIDA CONFORME A LA INVENCION COMPRENDE UNA CAPSULA U OTRA FORMA DE DOSIFICACION QUE TIENENUNA DIMENSION SUPERIOR A 2 MM Y CONTIENE UNO O MAS DE DICHAS UNIDADES. LA DENSIDAD DE CADA UNIDAD ES PREFERIBLEMENTE POR LO MENOS 2,5 Y USUALMENTE POR LO MENOS 2,7 G/ML Y PUEDEN CONSEGUIRSE DE FORMA CONVENIENTE INCLUYENDO AL MENOS EL 50% EN PESO DE UN AGENTE DE CARGA TAL COMO EL SULFATO BARICO.
ES87307973T 1986-09-18 1987-09-09 Formulacion farmaceutica. Expired - Lifetime ES2038669T3 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB8622482A GB8622482D0 (en) 1986-09-18 1986-09-18 Pharmaceutical formulation
GB8708011A GB8708011D0 (en) 1987-04-03 1987-04-03 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
ES2038669T3 true ES2038669T3 (es) 1993-08-01

Family

ID=26291305

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87307973T Expired - Lifetime ES2038669T3 (es) 1986-09-18 1987-09-09 Formulacion farmaceutica.

Country Status (10)

Country Link
US (1) US4938967A (es)
EP (1) EP0265061B1 (es)
KR (1) KR890004686B1 (es)
BE (1) BE1000616A5 (es)
CA (1) CA1302259C (es)
DE (1) DE3775880D1 (es)
DK (1) DK488287D0 (es)
ES (1) ES2038669T3 (es)
FR (1) FR2604090B1 (es)
GB (1) GB2196252B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US5374430A (en) * 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
DK165090D0 (da) * 1990-07-09 1990-07-09 Kem En Tec As Konglomererede partikler
GB9018839D0 (en) * 1990-08-29 1990-10-10 Newton John M Slow release compositions
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US6706188B2 (en) 1993-05-03 2004-03-16 Amersham Biociences Ab Process and means for down stream processing
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
WO1994003184A1 (en) * 1992-07-31 1994-02-17 Neose Pharmaceuticals, Inc. Compositions for treating and inhibiting gastric and duodenal ulcers
US5681581A (en) * 1992-08-04 1997-10-28 Dunn; James M. Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use
FR2703908B1 (fr) * 1993-04-13 1995-06-02 Asta Medica Ag Forme pharmaceutique pour administration rectale de composés pharmacologiquement actifs.
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US20120071710A1 (en) 1999-03-01 2012-03-22 Gazdzinski Robert F Endoscopic smart probe and method
US8636648B2 (en) 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US20050079214A1 (en) * 1999-09-01 2005-04-14 John Cooker Oral delivery system and method for making same
US20040101540A1 (en) * 1999-09-01 2004-05-27 John Cooker Oral delivery system and method for making same
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
EP1289645B1 (en) 2000-04-27 2007-06-13 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20110171296A1 (en) * 2000-10-30 2011-07-14 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
FI121528B (fi) * 2000-10-30 2010-12-31 Biohit Oyj Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
US6569808B2 (en) * 2001-07-30 2003-05-27 Lee F. Klinger Methods and compositions useful for bryophyte remediation to improve forest health and growth
US7131997B2 (en) 2002-03-29 2006-11-07 Scimed Life Systems, Inc. Tissue treatment
US20040076582A1 (en) * 2002-08-30 2004-04-22 Dimatteo Kristian Agent delivery particle
US7094369B2 (en) 2002-03-29 2006-08-22 Scimed Life Systems, Inc. Processes for manufacturing polymeric microspheres
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US8012454B2 (en) * 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US7976823B2 (en) 2003-08-29 2011-07-12 Boston Scientific Scimed, Inc. Ferromagnetic particles and methods
US20070102672A1 (en) * 2004-12-06 2007-05-10 Hamilton Judd D Ceramic radiation shielding material and method of preparation
KR20070115918A (ko) * 2005-01-31 2007-12-06 교린 세이야꾸 가부시키 가이샤 멀티플 유닛형 경구 서방성 제제 및 그 제조방법
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US7803413B2 (en) * 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
CN103463096B (zh) 2006-01-27 2016-03-16 耶鲁大学 胃酸分泌的快速作用抑制剂
CA2731653A1 (en) * 2008-07-22 2010-01-28 General Mills, Inc. Fruit products containing omega-3 fatty acids
US9486527B2 (en) 2009-05-08 2016-11-08 Emplicure Ab Composition for sustained drug delivery comprising geopolymeric binder
CN102458138B (zh) * 2009-06-05 2014-08-20 通用工厂公司 用于制备烘烤食品的胶囊化的ω-3脂肪酸

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB936386A (en) * 1959-01-16 1963-09-11 Wellcome Found Pellets for supplying biologically active substances to ruminants
GB1590573A (en) * 1976-08-06 1981-06-03 Atomic Energy Authority Uk Biologically active gels
GB1590574A (en) * 1976-08-06 1981-06-03 Atomic Energy Authority Uk Biologically active gels
GB1576376A (en) * 1977-03-30 1980-10-08 Benzon As Alfred Multiple-unit drug dose
GB2015875B (en) * 1978-02-24 1982-10-20 Novex Foreign Trade Co Ltd Solid oral pharaceutical product with increased efficacy and predetermined steady state of solubility
JPS6024767B2 (es) * 1979-08-24 1985-06-14 Shionogi Seiyaku Kk
GB2100602B (en) * 1981-06-24 1984-11-14 May & Baker Ltd Device for delivering biologically active substances to the digestive tract.
GB2123690A (en) * 1982-07-20 1984-02-08 Nat Res Dev Sustained release device
GB2123693B (en) * 1982-07-20 1987-05-13 Nat Res Dev Sustained release device
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag Sphaerische einkristalle fuer pharmazeutische zwecke
FR2560768A1 (fr) * 1984-03-07 1985-09-13 Crb Virbac Sa Dispositif a liberation programmee
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke Gmbh & Co Kg Pellet-zubereitung
US4609374A (en) * 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom

Also Published As

Publication number Publication date Type
FR2604090A1 (fr) 1988-03-25 application
GB2196252B (en) 1990-10-17 grant
GB8721186D0 (en) 1987-10-14 application
GB2196252A (en) 1988-04-27 application
KR890004686B1 (ko) 1989-11-25 grant
DE3775880D1 (es) 1992-02-20 grant
DK488287D0 (da) 1987-09-17 grant
FR2604090B1 (fr) 1990-06-15 grant
EP0265061A1 (en) 1988-04-27 application
DK488287A (da) 1988-03-19 application
CA1302259C (en) 1992-06-02 grant
US4938967A (en) 1990-07-03 grant
EP0265061B1 (en) 1992-01-08 grant
BE1000616A5 (fr) 1989-02-21 grant

Similar Documents

Publication Publication Date Title
Chumbley et al. The effect of indomethacin (an aspirin-like drug) on the rate of orthodontic tooth movement
Joy et al. Optic and peripheral neuritis: probable effect of prolonged chloramphenicol therapy
US3882246A (en) Treatment of skeletal muscle disorders with cyclobenzaprine
de Deuxchaisnes et al. The effect of low dosage glucocorticoids on bone mass in rheumatoid arthritis: a cross-sectional and a longitudinal study using single photon absorptiometry.
US6620836B1 (en) Antiarrhythmic and tranquilizer composition and treatment
Da Silva et al. Verapamil acute self-poisoning
Bedynek et al. Ventricular tachycardia: control by intermittent, intravenous administration of lidocaine hydrochloride
Laskin Acyclovir and suppression of frequently recurring herpetic whitlow
Schokker et al. The result of treatment of the masticatory system of chronic headache patients.
Riva Sanseverino Intensive medical physical treatment of osteoporosis with the AID of oxygen-ozone therapy
DE3341638A1 (de) Dreiphasen-praeparat zur empfaengnisverhuetung aus ethinyloestradiol und lynestrenol
Freinberg et al. Adjunctive ascorbic acid administration in antibiotic therapy
JPS63250318A (en) Pharmaceutical preparation suitable in oral cavity
US3903301A (en) Methods of treating muscular disorders
Keele et al. A study of bone density: comparison of the effects of sodium fluoride, inorganic phosphates, and an anabolic steroid (oxymetholone) on demineralized bone
Malik Early clinical response to different therapeutic regimens for human brucellosis.
Sanger et al. The oral and facial manifestations of dermatomyositis with calcinosis: report of a case
FR2285857A1 (fr) Agent de controle medical destine a etre administre par voie intravasculaire
CN2172661Y (zh) 一种药物枕
Carlsson et al. Failure to demonstrate antipyretic and analgesic properties of salicylamides.
Diefenbach et al. Digitoxin—A Critical Review
Charnot et al. Silicon, endocrine balance and mineral metabolism (calcium and magnesium)
JPS63183534A (en) Remedy for psoriasis
Rubin et al. An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 265061

Country of ref document: ES